Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other financing activities: 2009-2024

Historic Other financing activities for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $2.6 million.

  • Anika Therapeutics' Other financing activities fell 38.10% to $13,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 34.83%. This contributed to the annual value of $2.6 million for FY2024, which is 20.77% up from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Other financing activities is $2.6 million, which was up 20.77% from $2.2 million recorded in FY2023.
  • Over the past 5 years, Anika Therapeutics' Other financing activities peaked at $2.6 million during FY2024, and registered a low of $934,000 during FY2022.
  • For the 3-year period, Anika Therapeutics' Other financing activities averaged around $1.9 million, with its median value being $2.2 million (2023).
  • As far as peak fluctuations go, Anika Therapeutics' Other financing activities tumbled by 93.12% in 2020, and later soared by 130.41% in 2023.
  • Over the past 5 years, Anika Therapeutics' Other financing activities (Yearly) stood at $1.5 million in 2020, then declined by 25.98% to $1.1 million in 2021, then declined by 17.20% to $934,000 in 2022, then spiked by 130.41% to $2.2 million in 2023, then grew by 20.77% to $2.6 million in 2024.